Effect of Dual Angiopoietin-2/VEGF-A Inhibition with Faricimab▼ on Macular Anatomy in the STAIRWAY Phase 2 Study of Neovascular Age-Related Macular Degeneration

Faricimab▼ is a bispecific antibody that independently binds and neutralizes both Angiopoietin-2 (Ang-2) and VEGF-A. In preclinical studies, dual Ang-2/VEGF-A inhibition synergistically reduced inflammation, leakage and neovascularization, indicating vascular stabilization effect through combined Ang-2 and VEGF neutralization. The goal of this work was to examine the anatomical effects of faricimab▼ in the Phase 2 nAMD STAIRWAY study (NCT03038880) using multimodal imaging in the context of the preclinical data and Ang-2 biology.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.